Bio-Rad Laboratories Inc (BIO)
Official siteHEALTHCARE • MEDICAL DEVICES • NYSE
Market Cap: $9.85B
Last updated: Nov 17, 2026 at 11:05 AM ET
Bio-Rad Laboratories Inc (BIO) Earnings: Report Dates and Results
Bio-Rad Laboratories (BIO) is expected to report earnings on Feb 10, 2027. In the quarter ended Sep 30, 2026, Bio-Rad Laboratories reported EPS of $2.65, above the $2.61 estimate. It beat the EPS estimate in 6 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
BIO has an expected report date of Feb 10, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 13.9% above the $2.51 reported for the quarter ended Dec 31, 2025.
BIO Earnings Call
The latest BIO earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, BIO beat 28 and missed 12. Revenue for the quarter ended Sep 30, 2026 was $656.40M, up 0.5% from $653.00M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $2.65 | $2.61 | N/A | +1.53% | Beat | +17.3% | 2 | 0 up, 3 down | Nov 4, 2026 | $656.40M |
| Jun 30, 2026 | $2.62 | $2.34 | N/A | +11.97% | Beat | +0.4% | 3 | 0 up, 2 down | Aug 4, 2026 | $651.00M |
| Mar 31, 2026 | $1.89 | $1.99 | $1.86 - $2.14 | -5.03% | Miss | -25.6% | 3 | 1 up, 0 down | Apr 30, 2026 | $592.10M |
| Dec 31, 2025 | $2.51 | $2.70 | $2.49 - $2.92 | -7.04% | Miss | -13.4% | 4 | 0 up, 2 down | Feb 12, 2026 | $693.20M |
| Sep 30, 2025 | $2.26 | $1.93 | $1.56 - $2.20 | +17.10% | Beat | +12.4% | 4 | 4 up, 1 down | Oct 29, 2025 | $653.00M |
| Jun 30, 2025 | $2.61 | $1.75 | $1.60 - $1.92 | +49.14% | Beat | -16.1% | 5 | 1 up, 1 down | Jul 31, 2025 | $651.60M |
| Mar 31, 2025 | $2.54 | $1.78 | $1.47 - $1.96 | +42.70% | Beat | +10.9% | 5 | 1 up, 2 down | May 1, 2025 | $585.40M |
| Dec 31, 2024 | $2.90 | $2.88 | $2.73 - $2.98 | +0.69% | Beat | -6.5% | 5 | 0 up, 1 down | Feb 13, 2025 | $667.50M |
| Sep 30, 2024 | $2.01 | $1.18 | $0.86 - $1.30 | +70.34% | Beat | -13.7% | 6 | 0 up, 0 down | Oct 30, 2024 | $649.70M |
| Jun 30, 2024 | $3.11 | $2.02 | $1.86 - $2.20 | +53.96% | Beat | +3.7% | 5 | 0 up, 0 down | Aug 1, 2024 | $638.50M |
| Mar 31, 2024 | $2.29 | $2.14 | $2.02 - $2.29 | +7.01% | Beat | -31.4% | 5 | 0 up, 0 down | May 7, 2024 | $610.80M |
| Dec 31, 2023 | $3.10 | $2.87 | $2.58 - $3.00 | +8.01% | Beat | -6.3% | 5 | 0 up, 0 down | Feb 15, 2024 | $681.12M |
| Sep 30, 2023 | $2.33 | $2.81 | $2.62 - $2.92 | -17.08% | Miss | -10.4% | 5 | 0 up, 1 down | Oct 26, 2023 | $632.12M |
| Jun 30, 2023 | $3.00 | $2.68 | $2.53 - $2.89 | +11.94% | Beat | -11.2% | 6 | 1 up, 0 down | Aug 3, 2023 | $681.11M |
| Mar 31, 2023 | $3.34 | $3.48 | $3.21 - $4.08 | -4.02% | Miss | -32.4% | 5 | 0 up, 1 down | May 4, 2023 | $676.84M |
| Dec 31, 2022 | $3.31 | $3.44 | $3.34 - $3.62 | -3.78% | Miss | +3.1% | 5 | 0 up, 0 down | Feb 16, 2023 | $730.24M |
| Sep 30, 2022 | $2.60 | $2.77 | $2.59 - $3.01 | -6.14% | Miss | -29.9% | 4 | 0 up, 0 down | Oct 27, 2022 | $680.80M |
| Jun 30, 2022 | $3.38 | $2.77 | $2.46 - $2.98 | +22.02% | Beat | -4.5% | 3 | 0 up, 0 down | Jul 28, 2022 | $691.10M |
| Mar 31, 2022 | $4.94 | $3.23 | $2.80 - $3.98 | +52.94% | Beat | -5.2% | 3 | 0 up, 0 down | Apr 28, 2022 | $700.06M |
| Dec 31, 2021 | $3.21 | $2.87 | $2.79 - $2.93 | +11.85% | Beat | -20.0% | 4 | 0 up, 1 down | Feb 10, 2022 | $732.77M |
| Sep 30, 2021 | $3.71 | $2.48 | $2.30 - $2.82 | +49.60% | Beat | +23.7% | 4 | 0 up, 0 down | Oct 28, 2021 | $747.05M |
| Jun 30, 2021 | $3.54 | $2.70 | $1.90 - $3.19 | +31.11% | Beat | +119.9% | 4 | N/A | Jul 29, 2021 | $715.93M |
| Mar 31, 2021 | $5.21 | $2.94 | $2.50 - $3.30 | +77.21% | Beat | +172.8% | 4 | N/A | Apr 29, 2021 | $726.80M |
| Dec 31, 2020 | $4.01 | $3.32 | $3.10 - $3.46 | +20.78% | Beat | +72.8% | 4 | N/A | Feb 11, 2021 | $789.84M |
| Sep 30, 2020 | $3.00 | $1.82 | $1.75 - $1.85 | +64.84% | Beat | +86.3% | 4 | N/A | Oct 29, 2020 | $647.26M |
| Jun 30, 2020 | $1.61 | $1.15 | $1.01 - $1.45 | +40.00% | Beat | +2.5% | 4 | N/A | Jul 30, 2020 | $536.88M |
| Mar 31, 2020 | $1.91 | $1.57 | $1.40 - $1.77 | +21.66% | Beat | +15.8% | 4 | N/A | May 6, 2020 | $571.64M |
| Dec 31, 2019 | $2.32 | $2.45 | $2.40 - $2.47 | -5.31% | Miss | +8.9% | 4 | N/A | Feb 13, 2020 | $624.41M |
| Sep 30, 2019 | $1.61 | $1.41 | $1.36 - $1.45 | +14.18% | Beat | +76.9% | 2 | N/A | Oct 31, 2019 | $560.63M |
| Jun 30, 2019 | $1.57 | $1.34 | $1.22 - $1.56 | +17.16% | Beat | -4.3% | 4 | N/A | Aug 1, 2019 | $572.62M |
| Mar 31, 2019 | $1.65 | $1.09 | $0.97 - $1.26 | +51.38% | Beat | +65.0% | 4 | N/A | May 8, 2019 | $554.00M |
| Dec 31, 2018 | $2.13 | $1.70 | $1.48 - $1.86 | +25.29% | Beat | +317.6% | 4 | N/A | Feb 28, 2019 | $616.85M |
| Sep 30, 2018 | $0.91 | $1.14 | $0.90 - $1.45 | -20.18% | Miss | 0.0% | 6 | N/A | Nov 1, 2018 | $545.14M |
| Jun 30, 2018 | $1.64 | $1.28 | $1.11 - $1.45 | +28.13% | Beat | +864.7% | 3 | N/A | Aug 7, 2018 | $575.91M |
| Mar 31, 2018 | $1.00 | $1.22 | $0.68 - $1.31 | -18.03% | Miss | +143.9% | 3 | N/A | May 8, 2018 | $551.52M |
| Dec 31, 2017 | $0.51 | $1.26 | $1.19 - $1.33 | -59.52% | Miss | N/A | 4 | N/A | Feb 27, 2018 | $621.25M |
| Sep 30, 2017 | $0.91 | $0.60 | N/A | +51.67% | Beat | +46.8% | 4 | N/A | Nov 2, 2017 | $534.10M |
| Jun 30, 2017 | $0.17 | $0.68 | $0.36 - $0.78 | -75.00% | Miss | -72.1% | 4 | N/A | Aug 3, 2017 | $504.70M |
| Mar 31, 2017 | $0.41 | $0.27 | N/A | +51.85% | Beat | -2.4% | N/A | N/A | May 4, 2017 | $500.10M |
| Dec 31, 2016 | -$0.70 | $1.03 | N/A | -167.96% | Miss | -141.7% | N/A | N/A | Feb 23, 2017 | $571.45M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $9.92, down 3.8% from the year before. It was $0.95 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $9.92 | -3.8% |
| Dec 31, 2024 | $10.31 | -12.4% |
| Dec 31, 2023 | $11.77 | -17.3% |
| Dec 31, 2022 | $14.23 | -9.2% |
| Dec 31, 2021 | $15.67 | +48.8% |
| Dec 31, 2020 | $10.53 | +47.3% |
| Dec 31, 2019 | $7.15 | +25.9% |
| Dec 31, 2018 | $5.68 | +184.0% |
| Dec 31, 2017 | $2.00 | +110.5% |
| Dec 31, 2016 | $0.95 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,500 words across 8 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 4,466 | 8 | |
| 2026Q2 | Jun 30, 2026 | 6,081 | 9 | |
| 2026Q1 | Mar 31, 2026 | 5,939 | 10 | |
| 2025Q4 | Dec 31, 2025 | 4,486 | 9 | |
| 2025Q3 | Sep 30, 2025 | 4,548 | 10 | |
| 2025Q2 | Jun 30, 2025 | 5,731 | 12 | |
| 2025Q1 | Mar 31, 2025 | 5,501 | 11 | |
| 2024Q4 | Dec 31, 2024 | 6,086 | 11 |
2026Q3 Earnings Call
Opening remarks
Ruben Argueta Head of Investor Relations Thank you, operator. Good afternoon, everyone, and thank you for joining us. Today, we will review the financial results for the third quarter ended September 30, 2026, and provide an update on key business trends for Bio-Rad. With me on the call today are Norman Schwartz, our Chief Executive Officer; Jon DiVincenzo, President and Chief Operating Officer; and Roop Lakkaraju, Executive Vice President and Chief Financial Officer. Before we begin our review, I would like to remind everyone that we will be making forward-looking statements about management's goals, plans and expectations; our future financial performance; and other matters. These statements are based on assumptions and expectations of future events that are subject to risks and uncertainties. Our actual results may differ materially from these plans, goals and expectations. You should not place undue reliance on these forward-looking statements, and I encourage you to review our filings with the SEC, where we discuss in detail the risk factors in our business. The company does not intend to update any forward-looking statements made during the call today. Finally, our remarks today will include references to non-GAAP financials, including net income and diluted earnings per share, which are financial measures that are not defined under generally accepted accounting principles. In addition to excluding certain atypical and nonrecurring items, our non-GAAP financial measures exclude changes in the equity value of our stake in Sartorius AG in order to provide investors with a better understanding of Bio-Rad's underlying operational performance. Investors should review the reconciliation of these non-GAAP measures to the comparable GAAP results contained in our earnings release. We have also posted a supplemental earnings presentation in the Investor Relations section of our website for your reference. With that, I will now turn the call over to our Chief Operating Officer, Jon DiVincenzo.
Jon DiVincenzo President and Chief Operating Officer Thanks, Ruben. Good afternoon, everyone, and thank you for joining us. The third quarter represented another step forward in our efforts to improve Bio-Rad's operating and financial performance. Total company revenue in the third quarter was approximately $656 million, an increase of 0.5% on a reported basis and 0.7% on a currency-neutral basis compared with the prior year. This was our first quarter of currency-neutral growth this year. Gross margin expanded to 54.5% on a non-GAAP basis. While the pace of revenue growth remains modest, we are encouraged by the progress across several areas of the business. Clinical Diagnostics returned to growth, supported by Quality Systems and Diabetes products. In Life Science, excluding Process Chromatography, revenue increased 2.5% year-over-year. This represents the third consecutive quarter of sequential improvement in the growth rate. It was driven by our Genomics portfolio, including our Droplet Digital PCR business, led by the QX700 portfolio.
Frequently Asked Questions About BIO
When is Bio-Rad Laboratories's next earnings date?
Bio-Rad Laboratories's next earnings report is expected for Feb 10, 2027.
Did BIO beat earnings estimates last quarter?
Yes. Bio-Rad Laboratories reported EPS of $2.65 for the quarter ended Sep 30, 2026, above the $2.61 estimate, a 1.53% surprise.
What EPS do analysts expect from BIO next quarter?
The consensus EPS estimate for Bio-Rad Laboratories for the quarter ending Dec 31, 2026 is $2.86 from 4 analysts, with estimates from $2.68 to $3.07.
How often does BIO beat earnings estimates?
Bio-Rad Laboratories beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +13.88%.
BIO pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors